Wood J R, Green S B, Shapiro W R
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
J Clin Oncol. 1988 Feb;6(2):338-43. doi: 10.1200/JCO.1988.6.2.338.
The prognostic importance of tumor size was studied in 510 patients with malignant glioma (80% with glioblastoma multiforme) in the Valid Study Group of Study 80-01 of the Brain Tumor Study Group (now the Brain Tumor Cooperative Group [BTCG]). The endpoint was length of survival from randomization, which occurred within 3 weeks of definitive surgery. Following randomization, patients were scheduled to receive radiotherapy (RT) (6,020 cGy) during a 7-week period, along with continuing courses of chemotherapy. Computed tomographic (CT) scan information was available for 124 patients preoperatively, 300 patients postoperatively (preradiation), and 218 patients 9 weeks post-RT (+/- 3 weeks). Tumor size was determined as area (length x width) on the contrast-enhanced scan and survival was compared by log rank statistics. Preoperative tumor area was unrelated to survival (P = .48), but postoperative area was significantly prognostic (P less than .0001); the smaller the residual tumor, the longer the patient lived. Patients with a 75% or greater resection, as determined by measuring the difference between the preoperative and the postoperative scans, tended to have better survival, but the difference was not significant (P = .16). The post-RT area was strongly related to survival (P less than .00001). The percent change in area between the pre- and post-RT scans was also prognostic. Tumor size was of prognostic importance independent of the other known prognostic variables: age, Karnofsky performance score, and whether the tumor was glioblastoma or anaplastic astrocytoma. We conclude that the amount of tumor remaining after surgery is an important baseline variable at the start of RT, and that the tumor size 9 weeks following RT is also prognostic. Surgical resection is most important when it leaves the least amount of residual tumor.
脑肿瘤研究组(现脑肿瘤协作组[BTCG])80-01研究的有效研究组对510例恶性胶质瘤患者(80%为多形性胶质母细胞瘤)的肿瘤大小的预后重要性进行了研究。终点指标是自随机分组起的生存时长,随机分组在确定性手术后3周内进行。随机分组后,患者计划在7周内接受放疗(RT)(6020 cGy),同时持续进行化疗疗程。124例患者术前、300例患者术后(放疗前)以及218例患者放疗后9周(±3周)有计算机断层扫描(CT)信息。肿瘤大小通过增强扫描上的面积(长×宽)确定,并通过对数秩统计比较生存率。术前肿瘤面积与生存率无关(P = 0.48),但术后面积具有显著的预后意义(P < 0.0001);残留肿瘤越小,患者存活时间越长。通过测量术前和术后扫描的差异确定切除率达到75%或更高的患者往往生存情况更好,但差异不显著(P = 0.16)。放疗后面积与生存率密切相关(P < 0.00001)。放疗前后扫描面积的变化百分比也具有预后意义。肿瘤大小具有预后重要性,独立于其他已知的预后变量:年龄、卡诺夫斯基功能状态评分以及肿瘤是胶质母细胞瘤还是间变性星形细胞瘤。我们得出结论,手术后残留的肿瘤量是放疗开始时一个重要的基线变量,并且放疗后9周的肿瘤大小也具有预后意义。手术切除时残留肿瘤量最少最为重要。